Overview of the Downgrade#
Barclays has downgraded Tvardi Therapeutics Inc (NASDAQ:TVRD) from an Equalweight rating to Underweight. This change comes alongside a reduction in its price target from $4.00 to $3.00. Currently, the stock is trading at $3.39, reflecting an 80% decline over the past year.
Funding Concerns and Clinical Delays#
The downgrade is primarily due to concerns about funding, especially after Tvardi postponed its Phase 2 REVERT study for TTI-101, a drug aimed at treating liver cancer, from early to late 2026. This delay raises questions about the company’s financial stability, as they previously indicated they could sustain operations through the fourth quarter of 2026.
Recent Trial Results and Future Prospects#
In October, Tvardi reported disappointing results from another trial involving TTI-101 for idiopathic pulmonary fibrosis. The company is now focusing on TTI-109, a related drug that may help reduce side effects seen with TTI-101. However, Barclays noted that upcoming data in the second quarter is insufficient to support a positive outlook, as there is still a need to demonstrate the drug's effectiveness in clinical settings.
Analyst Perspectives#
Tvardi's market cap stands at approximately $31.8 million, with analyst price targets ranging widely from $3 to $15, indicating significant uncertainty. Other analysts, like Cantor Fitzgerald, have maintained a Neutral rating, while Lucid Capital Markets has upgraded the stock to Buy, setting a target at $6.00 based on its valuation relative to cash reserves. These differing views highlight the mixed sentiment surrounding Tvardi's financial health and drug development strategy.